Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NVCR

NVCR - Novocure Ltd Stock Price, Fair Value and News

$12.06+0.05 (+0.42%)
Market Closed

34/100

NVCR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

34/100

NVCR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NVCR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVCR Price Action

Last 7 days

-7.5%

Last 30 days

14.9%

Last 90 days

-9.5%

Trailing 12 Months

-39.9%

NVCR RSI Chart

NVCR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVCR Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-10.07

Price/Sales (Trailing)

2.09

EV/EBITDA

-11.82

Price/Free Cashflow

-18.13

NVCR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

655.4M

Rev. Growth (Yr)

8.11%

Rev. Growth (Qtr)

4.27%

NVCR Earnings

Earnings (TTM)

-136.2M

Earnings Growth (Yr)

62.84%

Earnings Growth (Qtr)

34.27%

NVCR Profitability

Operating Margin

74.54%

EBT Margin

-20.79%

Return on Equity

-40.01%

Return on Assets

-16.94%

Free Cashflow Yield

-5.51%

NVCR Investor Care

Shares Dilution (1Y)

3.53%

Diluted EPS (TTM)

-1.22

NVCR Alerts

  • 4 major insider sales recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025621.7M630.2M642.3M655.4M
2024525.7M550.0M577.7M605.2M
2023522.5M507.7M504.0M509.3M
2022537.9M545.2M542.6M537.8M
2021527.2M544.8M545.8M535.0M
2020379.8M409.0M449.6M494.4M
2019269.3M294.5M321.8M351.3M
2018194.3M217.4M232.1M248.1M
2017104.7M125.2M153.6M177.0M
201640.9M52.3M65.0M82.9M
201519.9M24.3M28.7M33.1M
20140012.9M15.5M
201300010.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Novocure Ltd

NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
 CEO
 WEBSITEnovocure.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES1320

Novocure Ltd Frequently Asked Questions

NVCR is the stock ticker symbol of Novocure Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Novocure Ltd is 1.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, NVCR's PE ratio (Price to Earnings) is -10.07 and Price to Sales (PS) ratio is 2.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Novocure Ltd has provided -0.002 (multiply by 100 for percentage) rate of return.